Improving the stability of 11C–labeled L-methionine with ascorbate

Background Carbon-11 labeled L-methionine ( 11 C–MET) is a popular tracer used in the clinic for imaging brain tumors with positron emission tomography. However, the stability of 11 C–MET in its final formulation is not well documented in literature. Recently, we observed fast degradation of HPLC-pu...

Full description

Saved in:
Bibliographic Details
Published in:EJNMMI radiopharmacy and chemistry 2017-10, Vol.2 (1), p.13-13, Article 13
Main Authors: Woods, Michael, Leung, Leo, Frantzen, Kari, Garrick, Jennifer G., Zhang, Zhengxing, Zhang, Chengcheng, English, Wade, Wilson, Don, Bénard, François, Lin, Kuo-Shyan
Format: Article
Language:English
Subjects:
Ascorbate
Ascorbic acid
Brain tumors
C-11 L-methionine
Degradation
High-performance liquid chromatography
Homocysteine, Methionine sulfoxide
Imaging
Medicine
Medicine & Public Health
Methionine
Methodology
Molecular Medicine
Neuroimaging
Nuclear Chemistry
Nuclear Medicine
Oxidation
Pharmacotherapy
Positron emission tomography
Radiology
Stability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Carbon-11 labeled L-methionine ( 11 C–MET) is a popular tracer used in the clinic for imaging brain tumors with positron emission tomography. However, the stability of 11 C–MET in its final formulation is not well documented in literature. Recently, we observed fast degradation of HPLC-purified 11 C–MET over time, and systematic investigation was conducted to identify the cause. Results In this study, we verified the degraded product as 11 C–labeled methionine sulfoxide ( 11 C–METSO). To minimize oxidation, ascorbate (100 ppm) was added to the HPLC eluant, and the resulting HPLC-purified 11 C–MET was stable in the final formulation solution without noticeable degradation for up to 1 h after the end of synthesis. Conclusions Our data suggest that to minimize degradation, ascorbate can be added to the 11 C–MET formulation solution especially if it is not administered into patients soon after the end of synthesis.
ISSN:2365-421X
2365-421X
DOI:10.1186/s41181-017-0032-x